1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers

Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers

  • July 2018
  • 23 pages
  • ID: 5480375
  • Format: PDF
  • By BCC Research

Summary

Table of Contents

Report Scope
The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

Report Includes
- An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
- Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
- A brief examination of the patent landscape
- Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
- Coverage of number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
- Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth

Report Scope
The report summarizes the current state of clinical research and trials, explains the impact of ACTs on the treatment of several metastasized malignancies, and also raises important concerns about the scalability and compatibility of TILs.

Report Includes
- An overview of both the problems and phenomenal opportunities with cell therapy and immunotherapy in general. While there are several biological and also commercial issues still to more completely resolve, perhaps the largest challenges are scalability and compatibility. Most developers begin by creating cell therapies for smaller groups of individuals, and then when they see real promise, the issue of scalability is addressed
- Detailed description about Adoptive Cell Therapy (ACT), how it targets the somatic mutations by infusion of autologous or redirected tumor-specific T-cells and its impact on the treatment of several metastasized malignancies
- A brief examination of the patent landscape
- Insight into the structure and function of T lymphocytes, identification of the different types of T lymphocytes as well as identifying the T Cell growth factor
- Coverage of number of clinical trials being conducted to investigate the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and investigate their use
- Evaluation of methods to improve TIL yield and tumor reactivity e.g. blockage of programmed cell death 1 (PD-1) and the effect of an agonistic 4-1BB antibody on TIL growth

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Pemphigus Vulgaris - Pipeline Review, H2 2019

Pemphigus Vulgaris - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Pemphigus Vulgaris - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2019, provides an overview of the Pemphigus ...

Caspase 9 - Pipeline Review, H2 2019

Caspase 9 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Caspase 9 - Pipeline Review, H2 2019SummaryCaspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) pipeline Target constitutes ...

Lupus Nephritis Global Clinical Trials Review, H2, 2019

Lupus Nephritis Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Lupus Nephritis Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Lupus Nephritis Global Clinical Trials Review, H2, 2019" provides an overview of Lupus Nephritis clinical trials ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on